Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas

Abstract Background Meningioma is a common primary central nervous system tumor that can cause a heavy burden on patients. Despite its well-established treatment modalities, pharmacological treatments are not sufficiently abundant. Therefore, we explored potential therapeutic targets for meningiomas...

Full description

Saved in:
Bibliographic Details
Main Authors: Yongxue Li, Lihao Lin, Wenhui Zhang, Yan Wang, Haoyu Shen, Yi Guan
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-03318-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849342435106226176
author Yongxue Li
Lihao Lin
Wenhui Zhang
Yan Wang
Haoyu Shen
Yi Guan
author_facet Yongxue Li
Lihao Lin
Wenhui Zhang
Yan Wang
Haoyu Shen
Yi Guan
author_sort Yongxue Li
collection DOAJ
description Abstract Background Meningioma is a common primary central nervous system tumor that can cause a heavy burden on patients. Despite its well-established treatment modalities, pharmacological treatments are not sufficiently abundant. Therefore, we explored potential therapeutic targets for meningiomas by integrating genomic and proteomic data. Methods We integrated meningioma data from the UK Biobank and Finnish databases and subsequently explored potential therapeutic targets for meningiomas through multi-omics data using bioinformatics techniques and Mendelian randomization. These targets were finally evaluated using phenotype-wide association group analysis. Results We found that BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3 can be potential therapeutic targets for meningiomas. Conclusion This study provides evidence and explores the biological significance of BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3 as potential therapeutic targets for meningiomas, providing new insights into the development of targeted therapy for meningiomas. Graphical abstract
format Article
id doaj-art-4484696ff3bb41efa80440deb473e3db
institution Kabale University
issn 2730-6011
language English
publishDate 2025-08-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-4484696ff3bb41efa80440deb473e3db2025-08-20T03:43:22ZengSpringerDiscover Oncology2730-60112025-08-0116111510.1007/s12672-025-03318-0Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomasYongxue Li0Lihao Lin1Wenhui Zhang2Yan Wang3Haoyu Shen4Yi Guan5Department of Neurosurgery, The First Hospital of Jilin UniversityDepartment of Neurosurgery, The First Hospital of Jilin UniversityDepartment of Neurosurgery, The Second Hospital of Tianjin Medical UniversityDepartment of Neurosurgery, The First Hospital of Jilin UniversityDepartment of Neurosurgery, The First Hospital of Jilin UniversityDepartment of Neurosurgery, The First Hospital of Jilin UniversityAbstract Background Meningioma is a common primary central nervous system tumor that can cause a heavy burden on patients. Despite its well-established treatment modalities, pharmacological treatments are not sufficiently abundant. Therefore, we explored potential therapeutic targets for meningiomas by integrating genomic and proteomic data. Methods We integrated meningioma data from the UK Biobank and Finnish databases and subsequently explored potential therapeutic targets for meningiomas through multi-omics data using bioinformatics techniques and Mendelian randomization. These targets were finally evaluated using phenotype-wide association group analysis. Results We found that BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3 can be potential therapeutic targets for meningiomas. Conclusion This study provides evidence and explores the biological significance of BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3 as potential therapeutic targets for meningiomas, providing new insights into the development of targeted therapy for meningiomas. Graphical abstracthttps://doi.org/10.1007/s12672-025-03318-0Mendelian randomizationMeningiomaTherapeutic targetGenome-wide association study
spellingShingle Yongxue Li
Lihao Lin
Wenhui Zhang
Yan Wang
Haoyu Shen
Yi Guan
Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas
Discover Oncology
Mendelian randomization
Meningioma
Therapeutic target
Genome-wide association study
title Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas
title_full Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas
title_fullStr Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas
title_full_unstemmed Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas
title_short Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas
title_sort multi omics and mendelian randomization study explores potential therapeutic targets for meningiomas
topic Mendelian randomization
Meningioma
Therapeutic target
Genome-wide association study
url https://doi.org/10.1007/s12672-025-03318-0
work_keys_str_mv AT yongxueli multiomicsandmendelianrandomizationstudyexplorespotentialtherapeutictargetsformeningiomas
AT lihaolin multiomicsandmendelianrandomizationstudyexplorespotentialtherapeutictargetsformeningiomas
AT wenhuizhang multiomicsandmendelianrandomizationstudyexplorespotentialtherapeutictargetsformeningiomas
AT yanwang multiomicsandmendelianrandomizationstudyexplorespotentialtherapeutictargetsformeningiomas
AT haoyushen multiomicsandmendelianrandomizationstudyexplorespotentialtherapeutictargetsformeningiomas
AT yiguan multiomicsandmendelianrandomizationstudyexplorespotentialtherapeutictargetsformeningiomas